LONDON: British biopharmaceutical company Avacta Group Plc (AVCT.L) said on Monday it has raised approximately £16 million ($20.5 million) in an oversubscribed share placing, providing it with working capital to progress its cancer drug development programs into the second half of 2026. The company, which is developing targeted cancer therapies using its pre|CISION platform,…
SYDNEY: TrivarX Ltd (ASX: TRI) said on Thursday it will acquire the intellectual property for Stabl-Im™, a novel brain cancer imaging technology, from Australian biotech firm Nucleics Pty Ltd, in a deal aimed at expanding its diagnostics portfolio into neuro-oncology. The Perth and Minneapolis-based company has entered a binding option agreement to acquire 100%…
WATERTOWN: EyePoint Pharmaceuticals, Inc. announced Monday it has commenced an underwritten public offering of $150 million of its common stock. The biopharmaceutical company, which focuses on treatments for serious retinal diseases, stated that all shares in the offering are being sold by the company. EyePoint also plans to grant the underwriters a 30-day option…